Article
Oncology
Min Ren, Jing Zhang, Yunyi Kong, Qianming Bai, Peng Qi, Ling Zhang, Qian Wang, Xiaoyan Zhou, Yong Chen, Xiaoli Zhu
Summary: Genetic alterations in Chinese melanoma patients show differences compared to Caucasian cohorts, with lower frequencies of BRAF and NRAS mutations. However, mutations in BRAF, C-KIT, and NRAS are consistent with clinicopathological features, and there is high concordance of gene mutations between primary and metastatic lesions.
ANNALS OF TRANSLATIONAL MEDICINE
(2022)
Article
Cell Biology
Joanna P. Wroblewska, Dora Dias-Santagata, Adam Ustaszewski, Cheng-Lin Wu, Masakazu Fujimoto, M. Angelica Selim, Wojciech Biernat, Janusz Rys, Andrzej Marszalek, Mai P. Hoang
Summary: The NRAS mutation is an independent predictor of worse survival in mucosal melanomas, while the significance of other related mutations remains unclear.
Article
Oncology
Seungyeon Jung, Emma Armstrong, Alexander Z. Wei, Fei Ye, Aaron Lee, Matteo S. Carlino, Ryan J. Sullivan, Richard D. Carvajal, Alexander N. Shoushtari, Douglas B. Johnson
Summary: This multicenter study highlights KIT alterations that are sensitive to imatinib and further supports the use of imatinib in subsets of KIT-altered melanoma.
BRITISH JOURNAL OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Thamila Kerkour, Catherine Zhou, Loes Hollestein, Antien Mooyaart
Summary: Studying primary melanoma and its metastasis is beneficial for understanding tumor biology and determining drug targets. This study analyzed literature systematically, evaluated gene concordance, and assessed heterogeneity. The results showed high concordance of drug targets during melanoma progression, but significant heterogeneity in gene consistency, requiring further validation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Filippo de Braud, Christophe Dooms, Rebecca S. Heist, Celeste Lebbe, Martin Wermke, Anas Gazzah, Dirk Schadendorf, Piotr Rutkowski, Juergen Wolf, Paolo A. Ascierto, Ignacio Gil-Bazo, Shumei Kato, Maria Wolodarski, Meredith McKean, Eva Munoz Couselo, Martin Sebastian, Armando Santoro, Vesselina Cooke, Luca Manganelli, Kitty Wan, Anil Gaur, Jaeyeon Kim, Giordano Caponigro, Xuan-Mai Couillebault, Helen Evans, Catarina D. Campbell, Sumit Basu, Michele Moschetta, Adil Daud
Summary: This study explores a targeted therapy for treating NRAS-mutant melanoma, showing promising antitumor activity in patients with the use of LXH254 and trametinib in combination.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Rita Casadonte, Mark Kriegsmann, Katharina Kriegsmann, Helene Streit, Rolf Ruediger Meliss, Cornelia S. L. Mueller, Joerg Kriegsmann
Summary: This study used proteomic technology to compare the molecular profiles of BRAF and NRAS mutated and wildtype melanoma patients' tissue samples. The results showed molecular differences between BRAF and NRAS mutated melanoma, and accurate identification was possible with an accuracy of 87-89% and 76-79% depending on the classification method.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Aleksandr S. Martianov, Natalia V. Mitiushkina, Anastasia N. Ershova, Darya E. Martynenko, Mikhail G. Bubnov, Priscilla Amankwah, Grigory A. Yanus, Svetlana N. Aleksakhina, Vladislav I. Tiurin, Aigul R. Venina, Aleksandra A. Anuskina, Yuliy A. Gorgul, Anna D. Shestakova, Mikhail A. Maidin, Alexey M. Belyaev, Liliya S. Baboshkina, Aglaya G. Iyevleva, Evgeny N. Imyanitov
Summary: This study analyzed the factors influencing the distribution of actionable genetic alterations in colorectal carcinomas. The study found that there were differences in the distribution of certain genetic alterations based on patients' age and gender. BRAF mutation frequency also showed geographic variation. In addition, a small fraction of CRCs had simultaneous alterations in more than one driver gene.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Hussein Akil, Mercedes Quintana, Jeremy H. Raymond, Tommy Billoux, Valentin Benboubker, Sophie Besse, Philippe Auzeloux, Veronique Delmas, Valerie Petit, Lionel Larue, Michel D'Incan, Francoise Degoul, Jacques Rouanet
Summary: Targeted radionuclide therapy (TRT) combined with MAPK/ERK inhibitors shows additive efficiency in BRAF and NRAS mutant melanoma cells. TRT has a significant therapeutic effect on NRAS(Q61K) mutated melanoma and reduces metastasis capacity.
Article
Veterinary Sciences
David Conrad, Alexandra Kehl, Christoph Beitzinger, Thomas Metzler, Katja Steiger, Nicole Pfarr, Konrad Fischer, Robert Klopfleisch, Heike Aupperle-Lellbach
Summary: This study aimed to detect mutant genes in digital melanoma and found that canine digital melanoma differs from canine oral melanoma and human melanoma, especially in the proportion of RAS mutations.
VETERINARY SCIENCES
(2022)
Review
Biology
Jiri Vachtenheim, Lubica Ondrusova
Summary: Advanced melanoma is difficult to cure, with resistant cells developing universally and requiring further drug therapy. Multiple mechanisms lead to the development of resistance, emphasizing the need for personalized treatment. Combined therapy may be an effective approach to reducing drug resistance.
Article
Biochemistry & Molecular Biology
Vlad-Adrian Afrasanie, Mihai-Vasile Marinca, Bogdan Gafton, Teodora Alexa-Stratulat, Alexandra Rusu, Eliza-Maria Froicu, Daniel Sur, Cristian Virgil Lungulescu, Larisa Popovici, Andrei-Vlad Lefter, Irina Afrasanie, Anca-Viorica Ivanov, Lucian Miron, Cristina Rusu
Summary: In this study, the frequency, distribution, coexistence, and clinicopathological and molecular correlations of RAS, BRAF, PIK3CA, and TP53 mutations were investigated in 104 patients with metastatic colorectal cancer from Northeastern Romania. TP53 was the most frequently mutated gene (73.1%), followed by KRAS (45.2%) and PIK3CA (6.7%). The study provides novel insights into genetic variations specific to the population from Northeastern Romania and enables the development of genetic profiles in a developing country with limited access to specialized genetic tests.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Lisa Dinter, Paula C. Karitzky, Alexander Schulz, Alexander A. Wurm, Marie-Christin Mehnert, Mildred Sergon, Antje Tunger, Mathias Lesche, Rebekka Wehner, Anja Mueller, Theresa Kaeubler, Heike Niessner, Andreas Dahl, Stefan Beissert, Marc Schmitz, Friedegund Meier, Barbara Seliger, Dana Westphal
Summary: This study investigated the combined effects of MEK inhibitors (MEKi) and BRAF inhibitors (BRAFi) on sensitive NRAS-mutant melanoma cells, including their ability to inhibit proliferation, induce apoptosis, and alter the expression of immune modulatory molecules. The study found that BRAFi significantly enhanced the antiproliferative and proapoptotic activity of MEKi, and upregulated the expression of immune relevant molecules in melanoma cells.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Costel Stelian Brinzan, Mariana Aschie, Georgeta Camelia Cozaru, Mariana Deacu, Eugen Dumitru, Ionut Burlacu, Anca Mitroi
Summary: In this study, the mutation frequencies of genes in Romanian colorectal cancer patients were analyzed and compared with clinicopathological variables. The results showed correlations between these mutations and distant metastasis at diagnosis, MSI-H, proximal colon location, and well/moderately differentiated tumors. The findings of this study are generally consistent with data from other populations.
Article
Medicine, General & Internal
Shen-Yi Lian, Lu-Xin Tan, Xin-Zhi Liu, Lu-Jing Yang, Ning-Ning Li, Qing Feng, Ping Wang, Yue Wang, Dong-Bo Qiao, Li-Xin Zhou, Ting-Ting Sun, Lin Wang, Ai-Wen Wu, Zhong-Wu Li
Summary: This study assessed the clinicopathological features and prognostic values of KRAS, NRAS, BRAF, and DNA mismatch repair status in colorectal cancer (CRC) in developing countries. The mutation frequencies of KRAS, NRAS, and BRAF were 41.7%, 1.6%, and 3.8%, respectively. KRAS mutations and deficient mismatch repair (dMMR) status were associated with aggressive biological behaviors and poor differentiation, while BRAF (V600E) mutations were associated with well-differentiated tumors. The dMMR status predicted longer overall survival in all CRC patients.
Article
Medicine, General & Internal
Aleksandra Bozyk, Pawel Krawczyk, Katarzyna Reszka, Kinga Krukowska, Agnieszka Kolak, Slawomir Mandziuk, Kamila Wojas-Krawczyk, Rodryg Ramlau, Janusz Milanowski
Summary: This study found that mutations in the KRAS, NRAS and BRAF genes are not random and depend on the localization of colorectal cancer tumors. The mutation detection rate was significantly higher in women than in men, and tumors in the rectum and sigmoid colon were the most commonly observed in all patients.
ARCHIVES OF MEDICAL SCIENCE
(2022)
